Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 13/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7194323 | 0.84 | TDP1 (0.50) | TDP1TSHRCYP3A4MAPTCACNA1B | |
| SCHEMBL21989095 | 0.82 | TDP1 (0.41) | TDP1TSHRCYP3A4MAPTCACNA1B | |
| SCHEMBL8909065 | 0.81 | CYP1A2 (0.50) | TDP1TSHRCYP3A4MAPT | |
| 3-Methylbutanoic Acid SCHEMBL9561318 | 0.79 | TDP1 (0.42) | TDP1TSHRCASP1CYP3A4MAPT | |
| SCHEMBL1289265 | 0.79 | TDP1 (0.44) | TDP1TSHRCYP3A4MAPTCACNA1B | |
| SCHEMBL9283778 | 0.79 | TDP1 (0.44) | TDP1TSHRCYP3A4MAPTCACNA1B | |
| SCHEMBL11213886 | 0.79 | TDP1 (0.44) | TDP1TSHRCYP3A4MAPTCACNA1B | |
| SCHEMBL27587694 | 0.78 | TDP1 (0.38) | TDP1TSHRCASP1CYP3A4MAPT | |
| SCHEMBL13908443 | 0.78 | TDP1 (0.43) | TDP1TSHRCYP3A4MAPTCACNA1B | |
| SCHEMBL28099722 | 0.78 | TDP1 (0.47) | TDP1TSHRCYP3A4MAPTCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11913049-B2 | Bioconversion of short-chain hydrocarbons to fuels and chemicals | Gonzalez, Ramon (US) | 2024-02-27 | — | — | US | claimed |
| US-20200347423-A1 | Bioconversion of Short-Chain Hydrocarbons to Fuels and Chemicals | GONZALEZ, RAMON | 2020-11-05 | — | — | US | claimed |
| US-20180355394-A1 | BIOCONVERSION OF SHORT-CHAIN HYDROCARBONS TO FUELS AND CHEMICALS | GONZALES RAMON (US) | 2018-12-13 | — | — | US | claimed |
| WO-2016161043-A1 | BIOCONVERSION OF SHORT-CHAIN HYDROCARBONS TO FUELS AND CHEMICALS | WILLIAM MARSH RICE UNIVERSITY (US) | 2016-10-06 | — | — | WO | claimed |
| JP-7258149-A | — | — | None | — | — | JP | disclosed |
| US-11913049-B2 | Bioconversion of short-chain hydrocarbons to fuels and chemicals | Gonzalez, Ramon (US) | 2024-02-27 | — | — | US | disclosed |
| US-20200347423-A1 | Bioconversion of Short-Chain Hydrocarbons to Fuels and Chemicals | GONZALEZ, RAMON | 2020-11-05 | — | — | US | disclosed |
| US-20180355394-A1 | BIOCONVERSION OF SHORT-CHAIN HYDROCARBONS TO FUELS AND CHEMICALS | GONZALES RAMON (US) | 2018-12-13 | — | — | US | disclosed |
| US-20170087205-A1 | Replacement Therapy for Natriuretic Peptide Deficiencies | PALATIN TECHNOLOGIES INC (US) | 2017-03-30 | — | — | US | disclosed |
| US-20160354443-A1 | Replacement Therapy for Natriuretic Peptide Deficiencies | PALATIN TECHNOLOGIES INC (US) | 2016-12-08 | — | — | US | disclosed |
| WO-2016161043-A1 | BIOCONVERSION OF SHORT-CHAIN HYDROCARBONS TO FUELS AND CHEMICALS | WILLIAM MARSH RICE UNIVERSITY (US) | 2016-10-06 | — | — | WO | disclosed |
| US-8828926-B2 | Uses of natriuretic peptide constructs | PALATIN TECHNOLOGIES, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8580746-B2 | Amide linkage cyclic natriuretic peptide constructs | PALATIN TECHNOLOGIES, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130274207-A9 | Uses of Natriuretic Peptide Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130045928-A1 | Uses of Natriuretic Peptide Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2013-02-21 | — | — | US | disclosed |
| US-20110263818-A1 | Peptidic Constructs with Amino Acid Surrogates | PALATIN TECHNOLOGIES, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20100035821-A1 | Amide Linkage Cyclic Natriuretic Peptide Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| WO-2003010566-A2 | PLASTIC LENS MATERIAL, PLASTIC LENS COMPOSITION, PLASTIC LENS OBTAINED BY CURING THE COMPOSITION AND PROCESS FOR PRODUCING THE PLASTIC LENS | SHOWA DENKO K. K. (JP) | 2003-02-06 | — | — | WO | disclosed |
| JP-H07258149-A | PRODUCTION OF 2-METHYLSUCCINIC ACID | KURARAY CO LTD | 1995-10-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263818-A1 | Peptidic Constructs with Amino Acid Surrogates | ARGLU1, QRFPR, ARG1 | TDP1 3303/4885TSHR 111/4885CASP1 3288/4885 |
| US-20130045928-A1 | Uses of Natriuretic Peptide Constructs | NPR1, NPPA, NPR3 | TDP1 2773/4885TSHR 227/4885CASP1 2428/4885 |
| US-20170087205-A1 | Replacement Therapy for Natriuretic Peptide Deficiencies | NPR1, NPR3, NPPA | TDP1 2232/4885TSHR 102/4885CASP1 4750/4885 |
| US-20100035821-A1 | Amide Linkage Cyclic Natriuretic Peptide Constructs | NPR1, NPR3, NPPA | TDP1 3851/4885TSHR 63/4885CASP1 4668/4885 |
| US-20130274207-A9 | Uses of Natriuretic Peptide Constructs | NPR1, NPPA, NPR3 | TDP1 2773/4885TSHR 227/4885CASP1 2428/4885 |
| US-20160354443-A1 | Replacement Therapy for Natriuretic Peptide Deficiencies | NPR1, NPR3, NPPA | TDP1 2232/4885TSHR 102/4885CASP1 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.